Canopy Growth sells Cannabinoid Compound's cannabinoid drug business to Dermapharm Holding. Canopy Growth will receive €80 million and another €42.6 million if Cannabinoid Compound reaches certain development milestones. The deal is scheduled to close by the end of January 2022.